ライフサイエンスコーパス: sentinel node

1 ping and an attempt to identify and remove a sentinel node.

2 discovered on frozen section analysis of the sentinel node.

3 e, resulting in intense blue staining of the sentinel node.

4 nation with blue dye for localization of the sentinel node.

5 ng and radioguided probe localization of the sentinel node.

6 e visualization and radiolocalization of the sentinel node.

7 performed in 157 women with a tumor-involved sentinel node.

8 may lead to incorrect identification of the sentinel node.

9 rapy is clear with the finding of a positive sentinel node.

10 ment of some melanoma micrometastasis in the sentinel node.

11 patients with a small tumour burden in their sentinel nodes.

12 aracterize its uptake by gastric and colonic sentinel nodes.

13 nts (85%), including 21 (55%) with bilateral sentinel nodes.

14 One patient had false-negative sentinel nodes.

15 and blue dyes, investigators are identifying sentinel nodes.

16 in any portion of the breast can drain to IM sentinel nodes.

17 Use of MOVA can improve identification of AX sentinel nodes.

18 ansit times from injection to arrival at the sentinel nodes.

19 r patients with histopathologically negative sentinel nodes.

20 ients with positive nodes had false-negative sentinel nodes.

21 ection was performed if tumor was present in sentinel nodes.

22 to identify draining lymphatic channels and sentinel nodes.

23 stasis and 70 patients (68%) with tumor-free sentinel nodes.

24 s with breast cancer and metastases in their sentinel nodes.

25 s similarity was also found in the number of sentinel nodes (171 in the first study and 173 in the se

26 l of 132 nodes were identified clinically as sentinel nodes; 65 (49%) were both blue and hot, 35 (27%

27 Of the 1425 patients with a positive sentinel node, 744 had been randomly assigned to axillar

28 omy (SLND) has confirmed that tumor-negative sentinel nodes accurately predict tumor-free axillary no

29 Our findings reinforce the concept that sentinel nodes act as pivotal sites for determining prog

30 the accuracy of intraoperative evaluation of sentinel nodes after neoadjuvant chemotherapy.

31 eries, so here is a surgeon's perspective on sentinel node and other oncological applications and on

32 tigraphy is reproducible in detection of the sentinel node and with the surgical probe helps effectiv

33 .3+/-4.6% among patients with tumor-positive sentinel nodes and 90.2+/-1.3% among those with tumor-ne

34 e assessed as having pathologically negative sentinel nodes and for whom follow-up data were availabl

35 5 assessable patients, 57 had tumor-positive sentinel nodes and one had an unsuccessful mapping proce

36 t micrometastases in four patients (three in sentinel nodes and one in a nonsentinel node).

37 scintigraphy, but reliable identification of sentinel nodes and their afferent lymph channels require

38 serving therapy and found to have a positive sentinel node, and can also be avoided in patients with

39 han thickness-matched controls, and positive sentinel nodes are limited to patients with thick primar

40 at SLNB after NAC is accurate when 3 or more sentinel nodes are obtained, but long-term outcomes are

41 Approximately one fifth of internal mammary sentinel nodes are pathologic, although most centers do

42 ted a technical success rate for identifying sentinel nodes at 96.2% with a false negative rate of 6.

43 ients with breast cancer who have a positive sentinel node, axillary lymph node dissection is the pre

44 Median tumor volume in positive sentinel node basins was 4.3 mm3 (range, 0.07 to 523 mm3

45 dity of intraoperative lymphatic mapping and sentinel node biopsy (LM/SNB) for staging the regional n

46 Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherap

47 rovide current recommendations on the use of sentinel node biopsy (SNB) for patients with early-stage

48 Sentinel node biopsy (SNB) has led to an increase in the

49 Worldwide, sentinel node biopsy (SNB) is now a standard staging pro

50 The benefit of adding sentinel node biopsy (SNB) to extended pelvic lymph node

51 ctive review revealed 33 women who underwent sentinel node biopsy after percutaneous core biopsy diag

52 for recent trials establishing the safety of sentinel node biopsy alone in patients with breast cance

53 plete axillary node dissection compared with sentinel node biopsy alone.

54 tion, he underwent a wide local excision and sentinel node biopsy for an acral melanoma on his left h

55 Can FDG PET/CT replace sentinel node biopsy for axillary staging?

56 In addition, the technique of dynamic sentinel node biopsy has been refined.

57 Sentinel node biopsy has been shown to extend disease fr

58 Surgical axillary staging via sentinel node biopsy in patients with benign axillary no

59 Sentinel node biopsy in patients with early breast cance

60 escalating role of nodal micrometastases and sentinel node biopsy in the definition of minimal region

61 est a therapeutic role for lymphatic mapping/sentinel node biopsy in the management and prognosis of

62 From 1998 to 2001, the use of sentinel node biopsy increased more than twofold in the

63 zed the transcriptional profiles of archival sentinel node biopsy specimens obtained from melanoma pa

64 mbers of patients and ideally should include sentinel node biopsy staging.

65 Sentinel node biopsy was successful in 30 women (91%) wi

66 ile carcinoma (n = 9) who were scheduled for sentinel node biopsy were prospectively included.

67 It has been substituted by sentinel node biopsy with dissection only if the sentine

68 tive radiotherapy are unknown, premastectomy sentinel node biopsy, delayed-immediate reconstruction,

69 with no palpable lymph nodes, compared with sentinel node biopsy, provides no survival benefit and i

70 to omit axillary dissection after a positive sentinel node biopsy, the panel recommends that these pa

71 sually mastectomy with axillary clearance or sentinel node biopsy.

72 ed from intraoperative lymphatic mapping and sentinel node biopsy.

73 ut the risks of surgery or even percutaneous sentinel node biopsy.

74 Forty-one patients underwent a sentinel node biopsy.

75 r, and who have 3 or fewer positive nodes on sentinel node biopsy.

76 She undergoes a wide local excision and sentinel node biopsy.

77 ically important application of percutaneous sentinel node biopsy.

78 been shown to improve patient selection for sentinel node biopsy.

79 Furthermore, discussions about the role of sentinel-node biopsy and tamoxifen in disease management

80 rimary melanomas according to the results of sentinel-node biopsy provides important prognostic infor

81 We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly

82 al relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if n

83 Sentinel-node biopsy, a minimally invasive procedure for

84 with palpable nodes or positive findings on sentinel-node biopsy, and no increased cardiovascular or

85 se (observation group), or wide excision and sentinel-node biopsy, with immediate lymphadenectomy for

86 Intraoperative evaluation of the sentinel node can determine the need for axillary dissec

87 Biopsy of sentinel nodes can predict the presence or absence of ax

88 before systemic therapy and suggest that the sentinel node concept is applicable following neoadjuvan

89 Completion ALND was performed only if sentinel nodes contained metastases or if they were not

90 sk of nonsentinel nodal involvement when the sentinel node contains tumor cells.

91 In total, 95% of the sentinel nodes could be intraoperatively visualized by m

92 nd injection), all preoperatively identified sentinel nodes could be localized using radio- and fluor

93 Sentinel nodes could not be distinguished reliably from

94 The number of sentinel nodes detected per patient ranged from 0 to 3 (

95 loid was 91% (the incidence of the number of sentinel nodes detected was 37.5%, 30.3%, 10.7%, and 21.

96 administration of a radiopharmaceutical for sentinel node detection and to characterize its uptake b

97 ommon iliac region is successful to identify sentinel nodes during laparoscopic surgery per hemipelvi

98 She underwent excision and sentinel node evaluation.

99 harvest this first draining node, termed the sentinel node, for examination.

100 r role as reliable markers for identifying a sentinel node from additional secondary lymph nodes that

101 sis (< or =2 mm), compared with 55% when the sentinel node had a macrometastasis (>2 mm).

102 nonsentinel node involvement was 7% when the sentinel node had a micrometastasis (< or =2 mm), compar

103 Patients with positive sentinel nodes have a significantly increased risk for r

104 90.2+/-1.3% among those with tumor-negative sentinel nodes (hazard ratio for death, 2.48; 95% CI, 1.

105 The sentinel node hypothesis assumes that a primary tumor dr

106 The concept of sentinel node identification and lymphatic mapping is al

107 r biopsy, and imaging view on the success of sentinel node identification and on the kinetics of radi

108 is study was to determine the feasibility of sentinel node identification in patients with invasive c

109 In vulvar and cervical carcinomas, sentinel node identification may significantly reduce th

110 e 13 who underwent lymphoscintigraphy twice, sentinel node identification was reproducible.

111 MOVA was compared with the anterior view for sentinel node identification.

112 All 39 patients had at least one sentinel node identified intraoperatively.

113 ive lymphoscintigraphy revealed at least one sentinel node in 33 patients (85%), including 21 (55%) w

114 al injection technique rapidly localizes the sentinel node in breast cancer, is an oncologically soun

115 ymph node dissection (CLND) after a positive sentinel node in patients with melanoma.

116 omponents of a multimarker panel to evaluate sentinel nodes in an on-going, multicenter clinical tria

117 success rates for identifying axillary (AX) sentinel nodes in breast cancer patients using preoperat

118 y is highly reproducible in the detection of sentinel nodes in melanoma patients.

119 apping were highly successful at identifying sentinel nodes in patients undergoing radical hysterecto

120 istochemical analysis, of initially negative sentinel nodes in patients with breast cancer.

121 le pyrogen-free I-methylene blue to identify sentinel nodes in patients with breast cancer.

122 Both sentinel nodes in the left groin were positive for melan

123 Applying IHC to the 157 tumor-free sentinel nodes in these 70 patients showed an additional

124 colloid, leading to the identification of 66 sentinel nodes in total.

125 e contained evidence of tumor if all tagged (sentinel) nodes in the same specimen were histopathology

126 er lymphoscintigraphic identification of the sentinel node, intraoperative gamma probe localization a

127 If a primary breast tumor is small and if sentinel node involvement is micrometastatic, then tumor

128 outcomes from randomized trials according to sentinel-node involvement have been lacking.

129 To determine whether the sentinel node is indeed the node most likely to harbor a

130 One sentinel node is negative for metastasis.

131 c mapping followed by lymphadenectomy if the sentinel node is positive.

132 inel node biopsy with dissection only if the sentinel node is positive.

133 If the sentinel node is tumor-free by both H&E and IHC, then th

134 ikely to contain tumor cells if the axillary sentinel node is tumor-free, but as yet no study has exa

135 Risk of positive sentinel nodes is lower in patients with DM compared to

136 location were evaluated for their effects on sentinel node localization and transit times from inject

137 The sentinel node localization approach showed a high negati

138 inical node-negative breast cancer underwent sentinel node localization study as part of a National C

139 y, with partial axillary node dissection and sentinel node mapping.

140 ases from T1/T2 lesions, or in patients with sentinel node metastases from T1a lesions.

141 Overall, sentinel node metastases were detected in 43 (41.8%) of

142 al trial, we randomly assigned patients with sentinel-node metastases detected by means of standard p

143 tion lymph-node dissection for patients with sentinel-node metastases is not clear.

144 ic survival among patients with melanoma and sentinel-node metastases.

145 nonsentinel node metastasis: the size of the sentinel node metastasis and the size of the primary tum

146 Progression occurred in 43% of patients with sentinel node metastasis, regardless of whether the hott

147 ection may not be necessary in patients with sentinel node micrometastases from T1/T2 lesions, or in

148 The incidence of sentinel-node micrometastases was 16.0% (122 of 764 pati

149 m)Tc-DTPA-mannosyl-dextran uptake by colonic sentinel nodes (n = 4) ranged from 0.54% to 2.4% of the

150 Uptake by gastric sentinel nodes (n = 6) ranged from 0.13% to 4.50%; all r

151 aluating the elimination of routine ALND for sentinel-node negative women to minimize the morbidity a

152 Therefore, one H&E sentinel node-negative patient (1.7%) was actually node-

153 and the IHC lymph node conversion rate from sentinel node-negative to sentinel node-positive was 6.4

154 Of the 218 patients with negative sentinel nodes, nonsentinel nodes were positive in 15 (f

155 etween the radioactive counting rates in the sentinel nodes of both scintigraphic studies was observe

156 100 patients: 42 patients had metastases in sentinel nodes; of these, 28 (66.7%) had no other involv

157 N0, oral cancer was tested by correlation of sentinel node pathologic status with that of nodes withi

158 nversion rate from sentinel node-negative to sentinel node-positive was 6.4% (10/157).

159 nts who were tumor-free by H&E actually were sentinel node-positive, and the IHC lymph node conversio

160 P = .001) were significantly associated with sentinel node positivity.

161 ast surgeons were more likely to perform the sentinel node procedure (P = 0.001).

162 The sentinel node procedure was done before (no-NACT) chemot

163 rospective chart review was performed of all sentinel node procedures for breast cancer from 2004 to

164 brid ICG-(99m)Tc-nanocolloid as a tracer for sentinel node procedures.

165 n and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary

166 be more detailed in examining the harvested sentinel node, providing more accurate staging informati

167 The mean number of sentinel nodes removed was 2.1.

168 Of seven patients with no identified sentinel nodes, six had a tumor-negative axilla.

169 olated tumor cells or micrometastases in the sentinel node (SLN).

170 If sentinel node (SN) biopsy (SNB) is accurate in this sett

171 our ongoing prospective multicenter trial of sentinel node (SN) biopsy indicate a 29.6% rate of micro

172 adio- and fluorescence image guidance during sentinel node (SN) biopsy procedures.

173 k, or on an extremity who were scheduled for sentinel node (SN) biopsy.

174 CT/CT over planar lymphoscintigraphy (PI) in sentinel node (SN) detection in malignancies with differ

175 99m)Tc-nanocolloid enables both preoperative sentinel node (SN) identification and intraoperative vis

176 LND was determined by comparing the rates of sentinel node (SN) identification and the incidence of S

177 ymphoscintigraphy and SPECT/CT, preoperative sentinel node (SN) identification can be difficult when

178 Increasing evidence supports that the sentinel node (SN) is at greatest risk for harboring met

179 influence of regression on the status of the sentinel node (SN) is controversial.

180 axillary dissection (ALND) in patients whose sentinel node (SN) is tumor-free.

181 mmediate complete lymphadenectomy (CLND) for sentinel node (SN) metastases, and WE plus postoperative

182 Approximately 20% of sentinel node (SN) positive melanoma patients have addit

183 urgeons at 13 institutions, examined whether sentinel node (SN) sampling accurately predicted LN stat

184 Few sentinel node (SN) studies in ovarian cancer have been r

185 reported frequency of internal mammary (IM) sentinel node (SN) visualization.

186 he microanatomy of lymphatic flow within the sentinel node (SN), and determine the prognostic accurac

187 ve the detection of occult metastases in the sentinel node (SN), compared with hematoxylin and eosin

188 e in the detection of micrometastases in the sentinel node (SN).

189 ter injection of 1% isosulfan blue, and both sentinel nodes (SNs) and non-SNs obtained during primary

190 o ovarian ligaments has been shown to detect sentinel nodes (SNs) in patients with ovarian cancer.

191 Patients with tumor-positive sentinel nodes (SNs) underwent completion dissections.

192 Patients with tumor-positive sentinel nodes (SNs) were considered for completion lymp

193 Sentinel nodes (SNs) were identified using blue dye and/

194 Age, MR, ulceration, LVI, regression, and sentinel node status were independent predictors of surv

195 axillary radiotherapy in case of a positive sentinel node, stratified by institution.

196 Sentinel nodes subjacent to hot spots were removed.

197 y, investigators have advocated applying the sentinel node technique to patients with cervical, endom

198 pendent prognostic variable in patients with sentinel nodes that were negative on initial examination

199 e that probe-guided resection of radioactive sentinel nodes (the first nodes that receive drainage fr

200 e analyzed to determine transit times to the sentinel node, the number of nodes visualized in early a

201 est that for women with metastases to 1 or 2 sentinel nodes, the radiation and systemic therapy that

202 In six (86%) of seven women with tumor in sentinel nodes, the sentinel nodes were the only nodes w

203 pping and a more detailed examination of the sentinel node to increase the accuracy of axillary stagi

204 oscintigraphic drainage patterns of a hybrid sentinel node tracer consisting of the fluorescent dye i

205 diation), patients with more than 3 positive sentinel nodes undergoing breast-conserving therapy, and

206 axillary metastases, patients with positive sentinel nodes undergoing mastectomy (who do not, as a s

207 m)Tc-DTPA-mannosyl-dextran demonstrated high sentinel node uptake and high concordance with isosulfan

208 rate for the identification and removal of a sentinel node was 84.8%.

209 The sensitivity of the sentinel node was 87.5% and the negative predictive valu

210 If the sentinel node was free of metastasis by hematoxylin and

211 The sentinel node was identified in 332 patients (93%) and w

212 A sentinel node was identified in all patients.

213 phatic drainage, and in all cases at least 1 sentinel node was identified.

214 The sentinel node was localized in 98.6% of the cases (419/4

215 had false-negative SLN biopsy; that is, the sentinel node was negative, but at least one nonsentinel

216 The sentinel node was successfully identified by blue dye in

217 psy group, the presence of metastases in the sentinel node was the most important prognostic factor;

218 Success in locating the sentinel node was unrelated to tumor size, type, locatio

219 The pathological status of the sentinel nodes was compared with that of the remaining a

220 Identification of AX sentinel nodes was equivalent with MOVA and anterior vie

221 Intraoperative analysis of sentinel nodes was performed using touch imprint and fro

222 i.e., depicted lymphatic channels leading to sentinel nodes) was 10 with 5.0-micron filtration and 19

223 These same sentinel nodes were also identified during the second sc

224 tions were evaluated, and count rates in the sentinel nodes were calculated and compared.

225 Sentinel nodes were detected in 11 of 12 patients, with

226 On average, 1.8 +/- 1.1 sentinel nodes were examined and 20.3 +/- 7.8 nonsentine

227 Sentinel nodes were examined by standard microscopy or i

228 All sentinel nodes were examined intraoperatively with froze

229 All sentinel nodes were excised.

230 Ex vivo, all radioactive sentinel nodes were fluorescent and vice versa.

231 Sentinel nodes were found at surgery in 30 women (91%).

232 the procedure was technically successful if sentinel nodes were found at surgery.

233 Sentinel nodes were found for 312 (96%) of 325 women and

234 Sentinel nodes were found in 12 (80%) of 15 women in the

235 IM or CL sentinel nodes were found in 19 (25%) cases and were not

236 sful radiocolloid localization, and positive sentinel nodes were found in 40 patients (18.6%).

237 asion; clean margins were obtained, and both sentinel nodes were free of cancer.

238 Sentinel nodes were free of tumor in 23 (77%) of 30 wome

239 Sentinel nodes were identifiable by blue color and by ra

240 Sentinel nodes were identified in 100 patients: 42 patie

241 Sentinel nodes were identified in 132 (99%) of 133 patie

242 Sentinel nodes were identified in 458 of 492 (92%) evalu

243 "Hot spots" representing underlying sentinel nodes were identified with a gamma probe.

244 Sentinel nodes were identified with both radioisotope an

245 Sentinel nodes were identified with radioisotope and blu

246 99mTc-sulfur colloid and continued until AX sentinel nodes were identified.

247 Three percent of positive sentinel nodes were in nonaxillary locations.

248 The remaining sentinel nodes were in the common iliac and para-aortic

249 Eighty percent of sentinel nodes were in three pelvic locations: iliac, ob

250 In the 60 patients whose sentinel nodes were metastasis-free by H&E and IHC, 1087

251 The sentinel nodes were outside the axilla in 8 percent of c

252 nts who had SNB and axillary dissection, the sentinel nodes were positive in 125 patients and were th

253 AX sentinel nodes were revealed in 75 (99%) cases.

254 Sentinel nodes were surgically localized using blue dye,

255 even women with tumor in sentinel nodes, the sentinel nodes were the only nodes with tumor.

256 In five of these patients, sentinel nodes were the only positive lymph nodes.

257 SLND was the only axillary surgery if sentinel nodes were tumor-free.

258 The accuracy of the sentinel nodes with respect to the positive or negative

259 Intraoperative evaluation of sentinel nodes with touch imprint and frozen section ana

260 t SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with mini